Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.

Size: px
Start display at page:

Download "Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014."

Transcription

1 Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management None Disclosures Arthur Agatston Conceptual Approach to CAD Risk Devereux Circulation,

2 Age Obesity Family Hx Diabetes Hypertension Thrombogenic RFs Obesity Diabetes Hypertension LDL CAC Tobacco LDL Family History Tobacco HDL 9p21 Fitness Microbiome HDL 9p21 Fitness Microbiome (Carnitine) Unknown Unknown Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis The New Prevention Strategy Known Family History Life Style Pre-Clinical Disease Silverman, MG. European Heart Journal December 23, 2013 Unknown 2

3 AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04 Family History Known Life Style Pre-Clinical Disease Framingham Risk Score Unknown AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04 FRS-Low Family History Known Life Style Pre-Clinical Disease AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04? Lp(a) Blocked arteries->bypass Surgery Calcium Score>1500 Unknown 3

4 AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04 Family History Known Life Style Clinical Disease AG-High Risk with Zero Risk Factors Risk of Heart Attack Calcium Score Unknown Lp(a),?HDL Dysfunction Number of (RF) Nasir K, Circ Cardiovasc Imaging. 2012; 5: PS 70 F TC=314,LDL=229 Known PS-The Power of Zero (MESA) Family History Life Style Calcium Score=0 Pre-Clinical Disease Unknown? Martin SA, Circulation. 2014;129:

5 PS 70 yo TC=314,LDL=229 Calcium Score=0, Large LDL Why FH and 0 CAC?? Large LDL Particles CAC in Familial Hypercholesterolemia n=107, 45+/-13, 36% DMW 56M CAC=750 age FH: father MI/CABG at 50, Brother MI age 50 CACS=1,386 1/11/08; CACS=1,000, 90th% Baptist; CACS= /31/01 per EBT; M.H. Miname et al. Atherosclerosis 213 (2010) CAC: 1/11/08 11/8/05 8/31/01 1,386 1,

6 High LDL, High CAC (MESA) CAC in Familial Hypercholesterolemia n=107, 45+/-13, 36% Martin SA, Circulation. 2014;129:77-86 M.H. Miname et al. Atherosclerosis 213 (2010) SS 70 M, DM, BP, BMI 27, TC, +FH,Low HDL, high TG, small LDL Diabetic, High Cholesterol, Multiple How to Treat? + Diabetes 6

7 Risk of Heart Attack SS-CAC=0 The Power of Zero Calcium Score CAC Score Groups Diabetes & no CAC Is Rx indicated? No MetS/DM (n= 4036 ) MetS without DM (n =1687) DM (n=882 ) CHD Event rate per 1000 Person Year ( ) 1.2 ( ) 1.6 ( ) ( ) 6.1 ( ) 9.1 ( ) ( ) 12.6 ( ) 13.4 ( ) Number of (RF) Nasir K, Circ Cardiovasc Imaging. 2012; 5: ( ) 15.3 ( ) 18.3 ( ) Malik S, Budoff M, Katz R, Blementhal RJ, Alain Bertoni, Blumenthal RS, Nasirk K, Szklo M, Barr G, Wong ND ( Diabetes Care 2012) AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04? Blocked arteries->bypass Surgery Calcium Score>1500 Why?? HDL Dysfunction 7

8 LDLR Cholesterol Pool HDL Metabolism Liver LDL/VLDL CETP HDL 2 ABCA1 NL Function HDL GGE (80 yo WF with Calcium Score=0) Apo A1 SRB1 HDL 3 ABCA1 Plaque Down Regulated ABCA1 Too Much HDL3 Liver HDL 2 ABCA1 SRB1 HDL 3 ABCA1 8

9 HDL Size Distribution Spectrum Healthy Un Healthy HDL Dysfunction Treatment BP-69 yo F- +FH No other known risk factors 4/17/00 4/16/01 TCS=1766 Stent Stent TG=142 HDL=120 LDL=100 LDL-S=267 Lp(a)=10 FRS=1%? Rx SRB1 Dysfunctional HDL-2 SRB-1 Model LDLR LDL/VLDL CETP Liver HDL 2 ABCA1 HDL 3 ABCA1 9

10 HDL GGE in SRB1/CETP Downregulation (HDL2 Bump) BP-69 yo F- +FH No other known risk factors 4/17/00 4/16/01 TCS=1766 Stent Stent TG=142 HDL=120 LDL=100 LDL-S=267 Lp(a)=10 FRS=1%? Rx BP-69 yo HDL 120, Low FRS, + FH BP Family (father 84-CAC rd %) HDL GGE BP-69F CAC~1800 HDL=120 SP-54M CAC=443 HDL=87 JP-47 CAC=596 HDL=113 10

11 M-T Family-father MI 42 JT-59F-CAC=2,267 HDL=144 JT-59F-CAC=2,267 HDL=144 JM-58M-CAC=494 HDL=88 GM 55M CAC=1,154 HDL=102 JT-59F-CAC=2,267 HDL=144 HDL Bump LDL Bump AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04 Calcium Score>

12 LW 64 WF-DM1-CAC=3,000 Father MI ~43 LW 64 WF-DM1-CAC=3,000 LW 64 WF-DM1-CAC=3,000 HDL in Type 1 Diabetes Epidemiology of Diabetes Complications Study Costacou, T, J Clin Lipidology 2011; 5:

13 Familial HDL Dysfunction Established Clinical CAD/Carotid Calcium Score > 75 th percentile Family h/o Premature CAD Low Risk Framingham Score Normal BMI Normal Insulin Sensitivity Elevated or Normal HDL/TG < 100 HDL 2 Bump NL LDL PPD/Small LDL Bump The Future of Coronary Imaging There is a lot more clinical information in CT and CTA Images Natural History of Atherosclerotic Plaque Natural History of the Post Rupture Lesions Fibrous tissue Calcium Old Young 13

14 Calcium Density of Coronary Artery Plaque and Risk of Incident Cardiovascular Events Old Young Youngest Younger MH Criqui, MJ Budoff,JAMA. 2014;311(3): Steady Athero Progression Arrested Progression due to Rx Individual Plaque Score Individual Plaque Score

15 SJ 70 F 2ppd smoker d/ced age 48 CAC-280 JCC-61: cac=79 belly fat resolved 20 yrs ago Late Onset due to Weight Gain Metabolic Syndrome or Young Patient AF 73 M CAC=274, from low score age 63 MS->DM2 x 10 yrs Individual Plaque Score

16 Young, Thrombogenic Event Individual Plaque Score 5 0 Devereux Circulation, 1993 PQ Thank You 16

17 Most People who Develop Heart Attacks have Normal LDL Values Heart attack with normal LDL Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Of 136,905 patients hospitalized with CAD, more than 75% had LDL levels below 130 mg/dl 23% had LDL-C <70 mg/dl 2011 CGHDI Sachdevaet al. AHJ, Vol 157, Jan 2009 Framingham-Total Cholesterol to HDL Ratio in those with and without future heart attacks AG-High Risk with Zero Risk Factors Lloyd-Jones DM, Arch Intern Med 2001;161: Silverman, MG. European Heart Journal December 23,

Who Cares About the Past?

Who Cares About the Past? Risk Factors, the New Calcium Score, Rheology and Atherosclerosis Progression Arthur Agatston 2/21/15 The Vulnerable Plaque vs. Plaque Burden CT Angiogram Is There a Role for Coronary Artery Calcium Scoring

More information

Khurram Nasir, MD MPH

Khurram Nasir, MD MPH Non-invasive CAD Screening Khurram Nasir, MD MPH Disclosures I have no relevant commercial relationships to disclose, and my presentation will not include off label or unapproved usage. HOW & WHAT WOULD

More information

Are We Ready for a Paradigm Shift From Risk Factors to Detection of Subclinical Coronary Atherosclerosis? Lessons From MESA. Khurram Nasir, MD MPH

Are We Ready for a Paradigm Shift From Risk Factors to Detection of Subclinical Coronary Atherosclerosis? Lessons From MESA. Khurram Nasir, MD MPH Are We Ready for a Paradigm Shift From Risk Factors to Detection of Subclinical Coronary Atherosclerosis? Lessons From MESA Khurram Nasir, MD MPH Disclosures No disclosures. Burden of Cardiovascular Disease

More information

Imaging-Guided Statin Allocation: Seeing Is Believing

Imaging-Guided Statin Allocation: Seeing Is Believing Imaging-Guided Statin Allocation: Seeing Is Believing The New Paradigm in Personalized Risk Assessment & Medication Prescribing Presented by: Michael J. Blaha May 15, 2014 1 General Principles of Talk

More information

Using Coronary Artery Calcium Score in the Quest for Cardiac Health. Robert J. Hage, D.O.

Using Coronary Artery Calcium Score in the Quest for Cardiac Health. Robert J. Hage, D.O. Using Coronary Artery Calcium Score in the Quest for Cardiac Health Robert J. Hage, D.O. Heart disease is the leading cause of death in the United States in both men and women. About 610,000 people die

More information

New Paradigms in Predicting CVD Risk

New Paradigms in Predicting CVD Risk New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease

More information

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2

More information

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for

More information

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Are Lipids (or Risk Factors) the Optimal Marker for ASCVD Risk Assessment? Time for Paradigm Shift? Franklin D. Roosevelt. Khurram Nasir, MD MPH

Are Lipids (or Risk Factors) the Optimal Marker for ASCVD Risk Assessment? Time for Paradigm Shift? Franklin D. Roosevelt. Khurram Nasir, MD MPH Are Lipids (or Risk Factors) the Optimal Marker for ASCVD Risk Assessment? Time for Paradigm Shift? Khurram Nasir, MD MPH How Cardiovascular Disease Became Our Biggest Threat? 1900-1940: Infectious diseases

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017 Coronary Artery Calcification Dharmendra A. Patel, MD MPH Director, Echocardiography Laboratory Associate Program Director Cardiovascular Disease Fellowship Program Erlanger Heart and Lung Institute UT

More information

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct

More information

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center

More information

Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice

Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation

More information

Colin Edwards Cardiologist Waitemata Health and Auckland Heart Group

Colin Edwards Cardiologist Waitemata Health and Auckland Heart Group Colin Edwards Cardiologist Waitemata Health and Auckland Heart Group June 2015 Disclosures PFIZER LECTURE SERIES Concepts in CV Risk Assessment Framingham Risk Atheroma Imaging Lifetime CV Risk 4 cases

More information

The Art of Cardiovascular Risk Assessment

The Art of Cardiovascular Risk Assessment The Art of Cardiovascular Risk Assessment Laurence S. Sperling, M.D., FACC, FACP,FAHA, FASPC Professor of Medicine (Cardiology) Professor of Global Health Director- Center for Heart Disease Prevention

More information

Cardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification

Cardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification Cardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification Matthew Budoff, MD, FACC, FAHA Professor of Medicine Director, Cardiac CT Harbor-UCLA Medical Center, Torrance, CA

More information

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space? Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09

More information

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive

More information

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology

More information

Assessing atherosclerotic risk for long term preventive treatment

Assessing atherosclerotic risk for long term preventive treatment Assessing atherosclerotic risk for long term preventive treatment Donald A. Smith, MD, MPH Endocrinologist, Clinical Lipidologist Associate Professor of Medicine and Preventive Medicine Icahn School of

More information

Learning Objectives. Patient Case

Learning Objectives. Patient Case Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:

More information

Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging

Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging Daniel S. Berman, MD Director, Cardiac Imaging Cedars-Sinai Heart Institute Professor of Medicine and Imaging Cedars-Sinai

More information

Hyperlipidemia. Intern Immersion Block 2015

Hyperlipidemia. Intern Immersion Block 2015 Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Coronary Artery Calcification

Coronary Artery Calcification Coronary Artery Calcification Julianna M. Czum, MD OBJECTIVES CORONARY ARTERY CALCIFICATION Julianna M. Czum, MD Dartmouth-Hitchcock Medical Center 1. To review the clinical significance of coronary heart

More information

Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis

Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis Mato Nagel, Ioan Duma, Constantina Vlad, Mandy Benke, Sylvia Nagorka Zentrum für Nephrologie & Stoffwechsel,

More information

4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose

4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose DYSLIPIDEMIA CASES Mary Malloy, MD I have nothing to disclose 1 Case 1 A 24 year old healthy, slender woman is referred because she has a family history of premature CAD (mother, age 59, had onset of angina

More information

9/3/ AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis. Disclosure

9/3/ AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis. Disclosure 2013 AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis Robert Gleeson MD Preven5ve Cardiology and Lipid Management Froedtert and The Medical College of Wisconsin Disclosure

More information

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of: Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Update on Cholesterol Management: The 2013 ACC/AHA Guidelines

Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College

More information

40% minimum reduction from

40% minimum reduction from 160 Circulatory Disease Mortality Target: Death rates in England 1993-2006 Persons under 75 Death / 100,000 population A fall of 44% over 10 years 140 120 100 80 60 40 20 141.0 84.2 Immortality guaranteed

More information

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for

More information

Coronary Artery Calcium. Vimal Ramjee, MD FACC The Chattanooga Heart Institute

Coronary Artery Calcium. Vimal Ramjee, MD FACC The Chattanooga Heart Institute Coronary Artery Calcium Vimal Ramjee, MD FACC The Chattanooga Heart Institute Disclosures I have no conflicts of interest to disclose. Objectives Recognize the utility of coronary artery calcium scoring

More information

Review current guideline recommendations for lipid-lowering therapy

Review current guideline recommendations for lipid-lowering therapy Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,

More information

Short and Long Term Prognosis after Coronary Artery Calcium Scoring

Short and Long Term Prognosis after Coronary Artery Calcium Scoring Short and Long Term Prognosis after Coronary Artery Calcium Scoring In Pre-Elderly and Elderly Patients Michael J. Blaha MD MPH Presented by: Michael J. Blaha July 24, 2017 1 Talk Outline 1. Coronary artery

More information

Prevention of Heart Disease: The New Guidelines

Prevention of Heart Disease: The New Guidelines Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

NEW GUIDELINES FOR CHOLESTEROL

NEW GUIDELINES FOR CHOLESTEROL NEW GUIDELINES FOR CHOLESTEROL NEW CHOLESTEROL GUIDELINES 2013 Recently updated guidelines for the treatment of high blood cholesterol levels is a major update since 2002. The news media have trumpeted

More information

CT Calcium Score and Statins in Primary CV Prevention. Dr Selwyn Wong

CT Calcium Score and Statins in Primary CV Prevention. Dr Selwyn Wong CT Calcium Score and Statins in Primary CV Prevention. Dr Selwyn Wong Promises, Pitfalls and Hard Truths of Coronary Calcium Scanning Selwyn Wong Ascot and Middlemore Hospitals Coronary Calcium Scoring

More information

Risk Factors for Heart Disease

Risk Factors for Heart Disease Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress

More information

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.

More information

David Ramenofsky, MD Bryan Kestenbaum, MD

David Ramenofsky, MD Bryan Kestenbaum, MD Association of Serum Phosphate Concentration with Vascular Calcification in Patients Free of Chronic Kidney Disease: The Multi Ethnic Study of Atherosclerosis David Ramenofsky, MD Bryan Kestenbaum, MD

More information

Lipoprotein Particle Profile

Lipoprotein Particle Profile Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

More information

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016 Is Universal Pediatric Lipid Screening Justified? YES Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016 None Disclosures What is a Pediatrician? Pediatrics is the specialty of medical science

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Disclosures CORONARY CALCIUM SCORING REVISITED. Learning Objectives. Scoring Methods. Consultant for M2S, Inc. Coronary Calcium Scoring: Software

Disclosures CORONARY CALCIUM SCORING REVISITED. Learning Objectives. Scoring Methods. Consultant for M2S, Inc. Coronary Calcium Scoring: Software CORONARY CALCIUM SCORING REVISITED Disclosures Consultant for M2S, Inc. Julianna M. Czum, MD Director, Division of Cardiothoracic Imaging Department of Radiology Dartmouth Hitchcock Medical Center Assistant

More information

Contemporary management of Dyslipidemia

Contemporary management of Dyslipidemia Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that

More information

Polish Your Practice Heart Failure. Why Prevent Vs. Treat? Coronary Heart Disease. A Challenging Patient:1994. Risk Factors for Heart Attack

Polish Your Practice Heart Failure. Why Prevent Vs. Treat? Coronary Heart Disease. A Challenging Patient:1994. Risk Factors for Heart Attack Polish Your Practice Heart Failure Lipid Management for the Prevention of Coronary Heart Disease in 2008 Carl E. Orringer, MD, FACC Clinical Associate Professor of Medicine Case Western Reserve University

More information

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

More information

Cardiovascular Risk Assessment Using Risk Scores in Primary Prevention. Khurram Nasir, MD MPH

Cardiovascular Risk Assessment Using Risk Scores in Primary Prevention. Khurram Nasir, MD MPH Cardiovascular Risk Assessment Using Risk Scores in Primary Prevention Khurram Nasir, MD MPH Cardiovascular Risk Assessment Using Risk Scores in Primary Prevention Khurram Nasir, MD MPH MSc Associate Professor

More information

Cardiac CT Angiography

Cardiac CT Angiography Cardiac CT Angiography Dr James Chafey, Radiologist Why do we need a better test for C.A.D? 1. CAD is the leading cause of death in the US CAD 31% Cancer 23% Stroke 7% 2. The prevalence of atherosclerosis

More information

Page 1. Disclosures. Background. No disclosures

Page 1. Disclosures. Background. No disclosures Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen

More information

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of

More information

Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil

Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil Defining Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD Brazil 1 Disclosure Honoraria received for consulting, speaker and or researcher activities : Astra Zeneca, Akcea, Amgen, Biolab, Esperion,

More information

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology

More information

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary 2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth

More information

Coronary Artery Calcium Scoring Mirvat Alasnag FACP, FRCP, FSCCT, FSCAI, FASE King Fahd Armed Forces Hospital, Jeddah. March 2017

Coronary Artery Calcium Scoring Mirvat Alasnag FACP, FRCP, FSCCT, FSCAI, FASE King Fahd Armed Forces Hospital, Jeddah. March 2017 Coronary Artery Calcium Scoring Mirvat Alasnag FACP, FRCP, FSCCT, FSCAI, FASE King Fahd Armed Forces Hospital, Jeddah March 2017 Newspapers Referrals 62 year old female CT chest and abdomen following

More information

Title for Paragraph Format Slide

Title for Paragraph Format Slide Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38

More information

DYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES

DYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES DYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES SATURDAY/4:30-5:30PM ACPE UAN: 0107-9999-17-249-L01-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists:

More information

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili

More information

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017 Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital

More information

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Cardiovascular Disease Prevention: Current Knowledge, Future Directions Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal

More information

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures. Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California

More information

COURAGE to Leave Diseased Arteries Alone

COURAGE to Leave Diseased Arteries Alone COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist

More information

Low HDL-levels: leave it or treat it?

Low HDL-levels: leave it or treat it? Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960

More information

Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors

Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention

More information

Life Science Journal 2018;15(12)

Life Science Journal 2018;15(12) Multicenter observational study of risk factors profile in a sample of Egyptian Patients with Acute Coronary Syndrome (part of Egyptian Cardiovascular Risk Factors Project) Prof. Dr. Ahmed Ashraf Reda,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Lipids: Translating Studies into Practice. WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH

Lipids: Translating Studies into Practice. WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH Lipids: Translating Studies into Practice WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH Discussants: Bob Gleeson, MD Assistant Professor of Medicine, General Internal Medicine Medical

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Beyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital

Beyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital Beyond Framingham Prediction of cardiovascular risk Niels van Pelt Cardiologist, Middlemore Hospital Niels Bohr (Danish Physicist)1885-1962 Prediction is very difficult, especially if it's about the future

More information

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION 1 A STUDY ON THE EFFECT OF DIET & LIFE STYLE ON THE INCIDENCE OF CORONARY ARTERY DISEASE IN MODERATELY DRINKING EX MILITARY MEN IN PATHANAMTHITTA DISTRICT. EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Atherosclerotic Disease Risk Score

Atherosclerotic Disease Risk Score Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,

More information

Potential recommendations for CT coronary angiography in athletes

Potential recommendations for CT coronary angiography in athletes Potential recommendations for CT coronary angiography in athletes B.K. Velthuis Dept. of Radiology UMC Utrecht, the Netherlands EuroPRevent 15 April 2011 Declaration of interest Philips Medical Systems

More information

Testing the Asymptomatic CAD Patient: When and Why?

Testing the Asymptomatic CAD Patient: When and Why? Testing the Asymptomatic CAD Patient: When and Why? Timothy M. Bateman M.D. Co-Director, Cardiovascular Radiologic Imaging Mid America Heart Institute Professor of Medicine University of Missouri-Kansas

More information

10/8/2015. MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH. None

10/8/2015. MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH. None MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH None 1 Objectives Why the need for change in the guidelines? What is the potential impact of these guidelines? Where do we go from here?

More information

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Lipids What s new (and what s not)

Lipids What s new (and what s not) Lipids What s new (and what s not) Overview Background evidence Obesity Guidelines Treatment options Pragmatic lipidology Side effects Familial Hypercholesterolaemia Cases Summary Background evidence CHD

More information

Lipids What s new? Meera Jain, MD Providence Portland Medical Center

Lipids What s new? Meera Jain, MD Providence Portland Medical Center Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?

More information

Latest Guidelines for Lipid Management

Latest Guidelines for Lipid Management Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline

More information

Lp(a) Ready for prime time? E Stroes AMC

Lp(a) Ready for prime time? E Stroes AMC Lp(a) Ready for prime time? E Stroes AMC Case Male, 45 years old Hypertension: DM: Smoking: Dyslipidemia: Fam history: brother MI (55yr) Lipoprotein(a): 1240 mg/l!!! Lipoprotein(a) = LDL + apo(a) tail

More information

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive

More information

HYPERLIPIDEMIA Liz Grant, MD. UNM Department of Family and Community Medicine July 2012

HYPERLIPIDEMIA Liz Grant, MD. UNM Department of Family and Community Medicine July 2012 HYPERLIPIDEMIA Liz Grant, MD UNM Department of Family and Community Medicine July 2012 Objective To be familiar with and able to apply screening and treatment guidelines to patients. Components of cholesterol

More information

Implementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines

Implementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines Summary Implementing new Dyslipidemia Guidelines Implementation of CV Risk and Dyslipidemia Guidelines Ronald D. Scott, MD Regional KPSC CVD Co-Lead Family Medicine and Lipidology, WLA ASCVD (Atherosclerotic

More information